tiprankstipranks
OncoCyte Corp (GB:0KCC)
LSE:0KCC

OncoCyte (0KCC) Ownership - Who Owns OncoCyte?

0 Followers

Recent Insider Trading Activity

Date
Name
Activity
Value
Apr 15, 2024Bought$7042200
Apr 15, 2024
Andrew Arno
Director
Bought$99999
Apr 15, 2024
Riggs Josh
Ceo & President,director
Bought$10001
Jun 15, 2023Bought$6300

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Dec 31, 2023Sold$179125

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
238,985Institution2.89%595,073
238,985Institution2.89%595,073
71,650Institution0.87%178,409
58,312Institution0.70%145,197
3,384Institution0.04%8,426
3,182Institution0.04%7,923
3,082Institution0.04%7,674
833Institution0.01%2,074
447Institution<0.01%1,113

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
238,985Institution2.89%595,073
58,312Institution0.70%145,197
3,384Institution0.04%8,426
3,182Institution0.04%7,923
833Institution0.01%2,074
447Institution<0.01%1,113

Top ETF Holders

Currently, No Data Available
Holder
# of Shares
Type
% Holding
Value

FAQ

Who Owns OncoCyte Corp (GB:0KCC)?
Currently, no data Available
What percentage of OncoCyte Corp (GB:0KCC) stock is held by institutional investors?
Currently, no data Available
What percentage of OncoCyte Corp (GB:0KCC) stock is held by retail investors?
Currently, no data Available
Who owns the most shares of OncoCyte Corp (GB:0KCC)?
Vanguard owns the most shares of OncoCyte Corp (GB:0KCC).
    What is the significance of the ownership structure for a publicly traded company?
    The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
      What's Included in PREMIUM?
      Make informed decisions based on Top Analysts' activity
      Know what industry insiders are buying
      Get actionable alerts from top Wall Street Analysts
      Find out before anyone else which stock is going to shoot up
      Get powerful stock screeners & detailed portfolio analysis